Survodutide
Dual GLP-1 / glucagon receptor agonist
- Class
- Dual agonist
- Half-life
- ~5-7 days
- Route
- Subcutaneous (SubQ)
- Cadence
- Weekly
- Evidence
- Human clinical trials
Overview
Survodutide is the first GLP-1/glucagon dual agonist to reach phase-3 testing for obesity and metabolic dysfunction–associated steatohepatitis (MASH). Once-weekly subcutaneous injection. In SYNCHRONIZE-1, the lead obesity trial that reported in June 2026, people on 6 mg lost a mean of 16.6% body weight over 76 weeks — comparable to Wegovy, a few percentage points behind tirzepatide. The standout finding wasn't the headline number: it was what happened inside — 63% liver fat reduction and 34% visceral fat reduction at the top dose, far exceeding what you'd predict from the total weight loss alone.
The dual-agonist design pairs GLP-1's appetite suppression with glucagon's thermogenic and hepatic fat-clearing effects. GLP-1 alone slows your stomach and quiets food cravings; glucagon alone would spike your blood sugar and feel miserable. Together — with the molecule deliberately biased toward GLP-1 — you get the satiety benefits plus direct fat mobilization in the liver and visceral depots, with acceptable glucose control. It's mechanistically distinct from tirzepatide (GLP-1/GIP) and semaglutide (GLP-1 only).
The drug is still investigational — not approved anywhere. Phase-3 results showed the expected GLP-1-class side effects (nausea, vomiting, diarrhoea during titration), plus a signal for higher heart rate that will be watched closely in the ongoing cardiovascular outcomes trial. If the MASH data hold up in the phase-3 LIVERAGE program, survodutide's real differentiation may be liver disease, not obesity alone.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved anywhere. All current use is investigational or research-market (unregulated peptide sourcing — purity/identity not guaranteed).
- GI side effects during titration are the dominant tolerability issue. Phase-2 obesity trial: 90.9% on survodutide had at least one adverse event vs 75.3% on placebo, mostly nausea, vomiting, diarrhoea. Severity usually mild-to-moderate; 3/67 people in early dose-finding had severe vomiting or diarrhoea.
- Heart rate: glucagon agonism can increase HR modestly. Phase-2 data flagged this; the ongoing SYNCHRONIZE-CVOT (cardiovascular outcomes trial, ~4,900 patients) is specifically designed to assess whether this translates to CV risk.
+ 3 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching Survodutide.
- Body composition via DEXA or MRI (lean mass matters — this drug may preserve it better than GLP-1 monoagonists)
- Liver fat (MRI-PDFF if accessible) + ALT/AST — primary mechanistic differentiator
- Fasting glucose + HbA1c — glucagon agonism can nudge glucose up in some people
- Resting heart rate — phase-2 data showed modest HR increases, being tracked in phase-3 CV outcomes trial
- Lipase + amylase if any upper abdominal pain — pancreatitis signal consistent with GLP-1 class
- Gallbladder symptoms — rapid weight loss increases stone/inflammation risk regardless of drug class
Frequently asked questions
What is Survodutide?
Dual GLP-1 / glucagon receptor agonist. Survodutide is the first GLP-1/glucagon dual agonist to reach phase-3 testing for obesity and metabolic dysfunction–associated steatohepatitis (MASH). Once-weekly subcutaneous injection. In SYNCHRONIZE-1, the lead obesity trial that reported in June 2026, people on 6 mg lost a mean of 16.6% body weight over 76 weeks — comparable to Wegovy, a few percentage points behind tirzepatide. The standout finding wasn't the headline number: it was what happened inside — 63% liver fat reduction and 34% visceral fat reduction at the top dose, far exceeding what you'd predict from the total weight loss alone.
How is Survodutide administered?
Subcutaneous (SubQ), typically weekly.
What is the half-life of Survodutide?
~5-7 days — Long-acting formulation engineered with C18 fatty diacid for once-weekly dosing.
Is Survodutide approved for human use?
Survodutide is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for Survodutide?
Evidence tier: Human clinical trials. SYNCHRONIZE-1 phase-3 (topline April 2026, full data NEJM June 2026): 726 adults, obesity without T2D, 76 weeks. Mean weight loss 16.6% at 6.0 mg vs 3.2% placebo. 28.5% achieved ≥20% loss at top dose.
What is commonly monitored when researching Survodutide?
Commonly tracked markers + signals: Body composition via DEXA or MRI (lean mass matters — this drug may preserve it better than GLP-1 monoagonists), Liver fat (MRI-PDFF if accessible) + ALT/AST — primary mechanistic differentiator, Fasting glucose + HbA1c — glucagon agonism can nudge glucose up in some people, Resting heart rate — phase-2 data showed modest HR increases, being tracked in phase-3 CV outcomes trial, Lipase + amylase if any upper abdominal pain — pancreatitis signal consistent with GLP-1 class, Gallbladder symptoms — rapid weight loss increases stone/inflammation risk regardless of drug class.
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.